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Shorter may be better
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A topic of much research and debate within cardiology has been
the optimal duration of dual antiplatelet therapy (DAPT) with
aspirin plus a P2Y12 inhibitor to prevent stent thrombosis and
further atherosclerotic progression after percutaneous coronary
intervention and implantation of a drug eluting stent. Recently,
large randomised controlled trials and observational studies
have been conducted in an attempt to determine the optimal
duration of DAPT, but the results were conflicting or
inconclusive.1-7 Indicative of the implications, this area of
cardiovascular research has had an effect on a broad range of
clinical practice guidelines.8-11 The common consensus among
experts has been that there is no “one size fits all” approach and
no common rule for the duration of DAPT after placement of
a drug eluting stent, but it is likely to be a case of “the longer
the better.” The current recommendation is for 12 months of
DAPT, but there are claims that this is actually of uncertain
value.12
The study byGargiulo and colleagues13 in TheBMJ (doi:10.1136/
bmj.i5483) adds some clarity to the debate on the duration of
DAPT. In a individual patient level meta-analysis, data were
pooled from 11 473 well matched randomised patients from six
large, multicentre, randomised controlled trials assessing short
term (≤6 months) versus long term (12 months) DAPT after
insertion of a drug eluting stent for stable ischaemic heart disease
or acute coronary syndrome.1-6 Not surprisingly, diabetes was
identified as an independent predictor of major adverse cardiac
events (MACE)—defined as cardiac death, myocardial
infarction, or definite or probable stent thrombosis (according
to criteria from the Academic Research Consortium14) at one
year after implantation of a drug eluting stent. Perhaps the most
notable finding of this meta-analysis was that long term DAPT
did not decrease the risk of MACE at one year compared with
short term DAPT in patients with diabetes (32% of the cohort)
and also in those without. Additionally, higher rates of bleeding
(defined according to commonly used criteria2-16) were observed
with long term DAPT, irrespective of diabetes status. The
researchers’ use of individual patient level data, prespecified
subgroup analyses, and sensitivity analyses make this a rigorous
assessment with high internal validity, and allowed conduct of
extended analysis. However, the patients within the trial cohorts
included in this analysis were prescribed clopidogrel and aspirin
for DAPT only. Studies involving analysis of aspirin plus newer
antiplatelet agents (prasugrel and ticagrelor) were not included.
This study complements work conducted so far on the use of
DAPT after implantation of a drug eluting stent. Such work
includes a studymost recently reported by the authors, in which
a pooled analysis of patient level data from four randomised
controlled trials was performed in all patients undergoing short
term versus longer term DAPT.17 The finding was that short
term DAPT was associated with similar rates of MACE but
lower rates of bleeding after stent implantation.17 The present
study13 is an extension of this work and looks at an important
and increasing population—patients with diabetes who are at
higher risk of ischaemic or thrombotic events and for whom
prolonged and even lifelong DAPT treatment could be
beneficial.18
The findings of Gargiulo and colleagues are important and
increasingly so because of the exponential increase in the global
prevalence of diabetes mellitus (particularly type 2 diabetes),
owing to risk factors related to increasingly poor lifestyles and
the emerging epidemic of obesity. Despite limitations, this study
provides robust data that contribute considerably to the debate
around DAPT duration, and could contribute towards reaching
a consensus for optimal length of treatment. It also highlights
the fact that having diabetes itself does not necessarily equate
to a requirement for longer duration of DAPT and that this can
actually do more harm than good.
Understanding the optimal duration of DAPT after percutaneous
coronary intervention and stent implantation is of clear clinical
and economic importance. Reducing costs to healthcare systems
resulting from medication provision, increased patient
surveillance, and the occurrence of adverse events (such as
ischaemic events from insufficient treatment and bleeding events
from prolonged treatment) is critical. Perhaps even more
important, however, is the need to minimise the burden of
treatment placed on patients (and possibly on their carers and
families) with the requirements of strict treatment adherence
and caution that comes in association with (potentially life
threatening) side effects and reduced quality of life. In context,
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the findings of Gargiulo and colleagues are hypothesis
generating but are promising. Further work is needed, for
example, by large, prospective, randomised controlled trials or
broader, patient level meta-analyses including newer P2Y12
inhibitors. Confirmation of Gargiulo and colleagues’ findings
could have a significant and definitive effect on clinical practice
and management guidelines for the optimal duration of DAPT
after percutaneous coronary intervention and implantation of a
drug eluting stent for the treatment of coronary artery disease
and acute coronary syndrome.
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